Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 185-191 , February 2006

Brain kinetics of the new selective serotonin transporter tracer [123I]ADAM in healthy young adults

  • Jan Booij

      Affiliations

    • Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 5662387; fax: +31 20 5669092.
    • ,
  • Maartje M.L. de Win

      Affiliations

    • Department of Radiology, Graduate School Neurosciences Amsterdam, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

Received 17 August 2005 ,Revised 26 September 2005 ,Accepted 3 October 2005.

References 

  1. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan A, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004;56:497–502
  2. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry. 2004;55:217–224
  3. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004;61:1271–1279
  4. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004;24:589–591
  5. Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med. 2005;46:973–977
  6. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003;60:1223–1229
  7. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings. Lancet. 1998;352:1433–1437
  8. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet. 2001;358:1864–1869
  9. Szabo Z, Kao PF, Scheffel U, Suehiro M, Mathews WB, Ravert HT, et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse. 1995;20:37–43
  10. Huang Y, Hwang DR, Narendran R, Sudo Y, Chatterjee R, Bae SA, et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab. 2002;22:1377–1398
  11. Shiue GG, Choi SR, Fang P, Hou C, Acton PD, Cardi C, et al. N,N-Dimethyl-2-(2-amino-4-18F-fluorophenylthio)-benzylamine (4-18F-ADAM): an improved PET radioligand for serotonin transporters. J Nucl Med. 2003;44:1890–1897
  12. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikitri MS, et al. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993;13:295–309
  13. Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with 123I-β-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med. 2000;41:36–44
  14. Booij J, Knol RJ, Reneman L, de Bruin K, Janssen AG, van Royen EA. Iodine-123 labelled nor-β-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats. Eur J Nucl Med. 1998;25:1666–1669
  15. Van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, et al. Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT. Neurobiol Aging. 2000;21:497–501
  16. Oya S, Choi SR, Hou C, Kung MP, Acton PD, Siciliano M, et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol. 2000;27:249–254
  17. Chalon S, Bronquard C, Vercouillie J, Kodas E, Garreau L, Bodard S, et al. ADAM is an effective tool for in vivo study of serotonergic function: validation in rat models. Synapse. 2004;52:136–142
  18. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, et al. Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain. Synapse. 2000;38:403–412
  19. Ye XX, Chen JC, Liu RS, et al. Microautoradiography of [123I]ADAM in mice treated with fluoxetine and serotonin reuptake inhibitors. Nucl Med Biol. 2004;31:557–562
  20. Acton PD, Choi SR, Hou C, Plossl K, Kung HF. Quantification of serotonin transporters in nonhuman primates using [123I]ADAM and SPECT. J Nucl Med. 2001;42:1556–1562
  21. Newberg AB, Plössl K, Mozley PD, et al. Biodistribution and imaging with 123I-ADAM: a serotonin transporter imaging agent. J Nucl Med. 2004;45:834–841
  22. Kauppinen TA, Bergstrom KA, Heikman P, Hiltunen J, Ahonen AK. Biodistribution an radiation dosimetry of [123I]ADAM in healthy human subjects: preliminary results. Eur J Nucl Med Mol Imaging. 2003;30:132–136
  23. Catafau AM, Pérez V, Penego M, Bullich S, Danús M, Puigdemont D, et al. SPECT of Serotonin Transporters Using 123I-ADAM: optimal imaging time after bolus injection and long-term test–retest in healthy volunteers. J Nucl Med. 2005;46:1301–1309
  24. Frokjaer VG, Pinborg LH, Madsen J, Knudsen GM. Evaluation of the serotonin transporter ligand [123I]ADAM for SPECT studies in humans. [abstract] Eur J Nucl Med Mol Imaging. 2004;31:S288
  25. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133–140
  26. de Win MML, Habraken JBA, Reneman L, van den Brink W, den Heeten GJ, Booij J. Measuring serotonin transporters with [123I]β-CIT SPECT: a double-blind, placebo-controlled, crossover validation study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology. 2005;30:996–1005
  27. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982–994
  28. Lin KJ, Yen TC, Wey SP, Hwang JJ, Ye XX, Tzen KY, et al. Characterization of the binding sites for 123I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography. J Nucl Med. 2004;45:673–681
  29. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231:258–261
  30. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24–42
  31. Reivich M, Amsterdam JD, Brunswick DJ, Shiue CY. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord. 2004;82:321–327
  32. Frankle WG, Huang Y, Hwang DR, Talbot PS, Slifstein M, Van Heertum R, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med. 2004;45:682–694
  33. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al. Regional distribution of serotonin transporter protein in postmortem human brain. Is the cerebellum a SERT-free brain region?. Nucl Med Biol. 2005;32:123–128
  34. Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, et al. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry. 2003;160:334–340
  35. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, Gouzoulis-Mayfrank E. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology. 2004;[10.1007/s00213-004-2002-8]
  36. Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, et al. Comparison of (+)-11C-McN5652 and 11C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med. 2002;43:678–692
  37. Malison RT, Laruelle M, Innis RB. Positron and single photon emission tomography. Principles and application in psychopharmacology. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press; 1995;p. 865–879
  38. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. [Review] Mol Imaging Biol. 2003;5:363–375
  39. Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879–1884
  40. Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnana G, Fujita M, Seibyl JP, et al. Sex differences in [123I]β-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41:275–284

PII: S0969-8051(05)00263-5

doi: 10.1016/j.nucmedbio.2005.10.005

Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 185-191 , February 2006

Article Tools

* Image Usage & Resolution